Niton (Nimodipine)

Nimodipine, the active ingredient in Niton, is a calcium channel blocker presented as a sterile intravenous injection. It is specifically indicated to prevent cerebral vasospasm after aneurysmal subarachnoid hemorrhage, thereby helping maintain adequate cerebral perfusion and reducing the risk of secondary ischemic injury in neurosurgical patients.

GNH USA supplies Niton as a licensed, GDP‑compliant international pharmaceutical product sourced from the European Union, meeting stringent quality standards, and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through reliable cold‑chain logistics.

Nimodipine is a cerebral vasodilator used in the management of vascular complications after subarachnoid hemorrhage.

Subarachnoid hemorrhage (post‑aneurysmal): Prevents cerebral vasospasm and supports cerebral blood flow. Aneurysmal SAH: Reduces incidence of delayed ischemic neurological deficits. Delayed cerebral ischemia: Lowers risk of secondary ischemic injury.

Nimodipine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: Mild decrease in blood pressure. - Headache: Transient headache. - Nausea: Mild gastrointestinal upset. - Flushing: Warm sensation and reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: Marked drop in blood pressure requiring intervention. - Cardiac arrhythmia: Irregular heart rhythm. - Allergic reaction: Anaphylaxis or severe skin rash.

When using Nimodipine, clinicians should observe several precautions to ensure patient safety and product integrity.

Dose adjustment: Required in patients with hepatic impairment. Blood pressure monitoring: Regular checks due to risk of hypotension. Concurrent vasodilators: Use with caution to avoid additive effects. Renal dysfunction: Monitor renal function as drug is partially excreted. Pregnancy and lactation: Use only if benefit outweighs risk. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Combined use with other potent vasodilators (e.g., nitroglycerin): May cause severe hypotension. - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Increase plasma levels, risk of toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): Decrease effectiveness. - Beta‑blockers: May enhance bradycardia. - Diuretics: May augment hypotensive effect.